Don't Wait for the Attack, Attack the Disease headlineDon't Wait for the Attack, Attack the Disease headline

See how GIVLAARI helps reduce AHP attacks

Fight AHP at its source
GIVLAARI® (givosiran) is the only treatment that targets
the cause of acute hepatic porphyria in the liver to help
reduce attacks.

Amalia, an artist and Alnylam
Patient Ambassador on GIVLAARI

Individual results may vary

Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI
Amalia, an artist and Alnylam Patient Ambassador on GIVLAARI

Don't Wait for the Attack, Attack the Disease headlineDon't Wait for the Attack, Attack the Disease headline

Amalia, an artist and Alnylam
Patient Ambassador on GIVLAARI

Individual results may vary

See how GIVLAARI helps reduce AHP attacks

Fight AHP at its source
GIVLAARI® (givosiran) is the only treatment that targets
the cause of acute hepatic porphyria in the liver to help
reduce attacks.

Treatment with GIVLAARI

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults

Monthly appointment calendar

Once-monthly dosing

GIVLAARI is given once a month as a subcutaneous injection (under the skin) by a healthcare professional.

Reduces levels of toxins icon

Reduces levels of toxins

GIVLAARI reduces levels of 
delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), toxins associated with attacks and other AHP symptoms.

Fewer porphyria attacks icon

Fewer porphyria attacks

In a 6-month study, on average, patients with AHP had their attacks reduced by 70% after receiving GIVLAARI compared with those receiving placebo.

Fewer days of hemin use icon

Fewer days of hemin use

In a 6-month study, on average, patients with AHP had 70% fewer days of hemin use after receiving GIVLAARI compared with those receiving placebo.

Side effects icon

Most common side effects

In a 6-month study, the most common side effects of GIVLAARI were nausea and injection site reactions.

36 months icon

After the 6-month study, patients with AHP experienced fewer attacks with continued treatment.

Attacks were defined as those that required hospitalization, urgent healthcare visit, or intravenous (IV) hemin administration at home.

Stay updated

Sign up for the latest news about GIVLAARI

All fields are required.

I am a:

Patient
Caregiver
Medical Professional
Other
 
 

IMPORTANT SAFETY INFORMATION 

Do not use GIVLAARI® (givosiran) if you have ever had a severe allergic reaction to GIVLAARI.

GIVLAARI can cause:

  • Severe allergic reaction

    Tell your doctor or nurse right away if you experience any of the following signs or symptoms of a severe allergic reaction during treatment:

    • Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
    • Breathing problems or wheezing
    • Feeling dizzy or fainting
    • Rash or hives
    • Itching

    If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.

  • Liver problems

    Your doctor will check your liver function by doing blood tests:

    • Before you start using GIVLAARI
    • Once a month for the first 6 months of treatment
    • And when they think it is needed

    If these tests show abnormal results, your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

  • Kidney problems

    Your doctor will check how your kidneys are working while you are using GIVLAARI.

  • Injection site reactions

    GIVLAARI is given as an injection under the skin (called a “subcutaneous injection”). Reactions to this injection may happen during treatment with GIVLAARI.

    Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.

  • Increased blood homocysteine levels

    GIVLAARI may cause increased levels of homocysteine (a type of amino acid) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests. If your levels are increased, your doctor may check your folate, vitamins B12 and B6, and tell you to take a vitamin B6 supplement.

  • Inflammation of the pancreas (pancreatitis)

    Cases of acute pancreatitis including some that were severe, have been reported in patients receiving GIVLAARI. If you have a severe case of acute pancreatitis your doctor or nurse will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

What are the common side effects of GIVLAARI?

The most common side effects of GIVLAARI are nausea and injection site reactions. These are not all the possible side effects of GIVLAARI. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-8 00-FDA -1088.


WHAT IS GIVLAARI?

GIVLAARI is a prescription medicine used to treat acute hepatic porphyria (AHP) in adults.


For additional information about GIVLAARI, please see full Prescribing Information.